SR
VRTX icon

Swiss Re’s Vertex Pharmaceuticals VRTX Stock Holding History

Swiss Re’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Buy
345
+284
+466% +$126K 0.02% 146
2026
Q1 		$27.2K Hold
61
– – 0.17% 88
2025
Q4 		$27.7K Buy
+61
New +$26.3K ﹤0.01% 85

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Swiss Re's VRTX Position: Q2 2026 in Review

Swiss Re increased its Vertex Pharmaceuticals (VRTX) stake by 466% in Q2 2026, buying an estimated $126K and bringing the position to 345 shares worth $171K. The position accounts for 0.02% of the portfolio, ranked #146.

Swiss Re first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Swiss Re held 345 shares of Vertex Pharmaceuticals worth $171K as of Q2 2026.
  • Swiss Re bought 284 Vertex Pharmaceuticals shares in Q2 2026, an estimated $126K.
  • Vertex Pharmaceuticals made up 0.02% of Swiss Re's portfolio in Q2 2026, its #146 holding.
  • Swiss Re first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Swiss Re's 13F filing for Q2 2026, filed 11 Aug 2026.